Eisai

Keisuke Naito, Executive Vice President and Chief Ecosystem Officer, oversees Eisai's external innovation and venture activities. He reports to CEO Haruo Naito, his father, who has led the company since 1992. The dual family-operator structure means Eisai's venture decisions are made by the same executives who oversee the company's $5.4 billion pharmaceutical business, not by an independent fund manager.

Eisai sources through its global research hubs — the G2D2 lab in Cambridge, Massachusetts, the EMEA Knowledge Centre in Hatfield, UK, and its Tokyo headquarters — as well as its membership in Japan's AMED and Haruo Naito's World Economic Forum relationships. The firm publishes academic research and clinical data aggressively, which creates inbound flow from founders working on Alzheimer's, Parkinson's, and other neurology targets that align with Eisai's therapeutic pipeline.

Eisai Innovation is not a separate fund; it is a corporate function investing from the balance sheet with no external limited partners. Startups that receive Eisai capital typically enter into a broader strategic collaboration that includes access to clinical trial infrastructure, regulatory expertise, and potential licensing agreements. This aligns the venture activity with Eisai's core drug-development mission rather than a standalone financial return objective.

Eisai typically seeks observer rights or strategic collaboration board positions rather than lead-investor control, preserving the startup's independence while ensuring visibility into clinical data and pipeline decisions. This is consistent with the firm's public statements on partnership philosophy — they want to integrate science, not acquire startups outright.

Eisai Innovation does not invest in therapeutic areas outside its parent company's focus — you will not see medical devices, surgical robotics, or general healthcare services. They also avoid asset classes unrelated to their core mission; there is no real estate, infrastructure, or crossover hedge fund activity. The venture mandate is cleanly restricted to neurology, oncology, and the digital-tool and AI/drug-discovery platforms that accelerate those pipelines.

The Leqembi approval in 2023 validated Eisai's three-decade bet on amyloid-targeting therapies, and the company now uses its Alzheimer's clinical infrastructure as a magnet for early-stage biotech. Startups working on biomarkers, patient screening, or disease-modifying mechanisms can gain access to Eisai's patient cohorts and trial sites — a competitive advantage that pure-play VCs cannot offer and that Eisai actively markets to biotech founders.

Eisai operates the Eisai USA Foundation, which is legally separate from both the pharmaceutical business and Eisai Innovation. The foundation focuses on patient access, Alzheimer's caregiver support, and global health equity — activities that reinforce the company's public-health brand but do not involve venture investing or equity positions in startups.